# US 2025/0145664 A1 · Pharmaceutical compositions for imaging, diagnosis and treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145664 A1
- Document ID: US20250145664A1
- Status: Published application
- Kind: A1
- Application number: 19/020,677
- Filed: 2025-01-14
- Published: 2025-05-08
- Earliest claimed: 2021-09-13
- Assignees: Jubilant Draximage Inc.
- Applicants: Jubilant Draximage Inc.
- Inventors: Vijayaraj Kuniyil Kulangara; Riadh Zriba; Tusharmouli Mukherjee; Indranil Nandi; Miriam Ruiz Pena
- Web page: https://patentgrep.com/patent/US20250145664A1

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- C07K 7/06: having 5 to 11 amino acids
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 51/041: {Heterocyclic compounds}
- A61K 51/083: {the peptide being octreotide or a somatostatin-receptor-binding peptide}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical cold kit composition comprising a chelating agent linked to somatostatin receptor binding organic moiety, a stabilizer, a buffer, and a caking agent or bulking agent, wherein the composition is free of sequestering agent. Further, the present invention also relates to the process of preparing reconstituted or radiolabeled solution composition having high in use stability and radiochemical purity and use thereof for diagnostic and/or therapeutic purposes.

## Claims

### Claim 1

A reconstituted radiopharmaceutical composition in a single vial, comprising:
(a) a radioisotope labeled complex comprising a chelating agent linked to somatostatin receptor binding organic moiety;
(b) at least one stabilizer selected from the group consisting of ascorbic acid, sodium bisulfite, gentisic acid, glutamate, metabisulfite, monothioglycerol, propyl gallate, sulfite sodium, tocopherol alpha, thioglycolate, formaldehyde sulfoxylate sodium, histidine, melatonin and combinations thereof;
(c) a buffer selected from the group consisting of sodium acetate, sodium succinate, tartrate, citrate, formate, HEPES buffer, lactate, TRIS, phosphate, borate, bicarbonate, carbonate, morpholine propanesulphonic acid, arginine and combinations thereof; and
(d) a bulking agent selected from the group consisting of sodium chloride, gelatin, mannitol, inositol, sorbitol, polyethylene glycol, polyvinyl pyrrolidone (PVP) and combinations thereof;
wherein the composition is free of sequestering agent and wherein the radiochemical purity of radiolabeled composition is at least 95 percent immediately after reconstitution.

### Claim 2 (depends on 1)

The reconstituted radiopharmaceutical composition of claim 1, wherein the radioisotope is selected from copper-64, gallium-68, gallium-67, gallium-66, lutetium-177, yttrium-86, yttrium-90, technetium-99, indium-114, indium-111, scandium-47, scandium-44, scandium-43, zirconium-89, bismuth-213, bismuth-212, actinium-225, lead-212, rhenium-188, rhenium-186, and rubidium-82.

### Claim 3 (depends on 1)

The reconstituted radiopharmaceutical composition of claim 1, wherein the chelating agent is selected from the group consisting of DOTA, TETA, NOTA, DTPA, NTA, EDTA, D03A, NOC, DOTAGA, HBED, HBECC, NODAGA, DFO, EDTA, 6SS, B6SS, PLED, TAME, YM103, and H2dedpa.

### Claim 4 (depends on 1)

The reconstituted radiopharmaceutical composition of claim 1, wherein the chelating agent linked to somatostatin receptor binding organic moiety is selected from DOTATOC, DOTATATE and DOTANOC.

### Claim 5 (depends on 1)

The reconstituted radiopharmaceutical composition of claim 1, wherein the pH of the composition ranges from 2 to 8.

### Claim 6 (depends on 1)

The reconstituted radiopharmaceutical composition of claim 1, wherein the pH of the composition is within 0.5 pH units of the initial pH level after storage at 25±2° C. and 60±5% relative humidity for 3 hours.

### Claim 7 (depends on 1)

A process for preparing the reconstituted radiopharmaceutical composition of claim 1, the process comprising:
a) adding suitable quantities of one or more bulking agent, one or more stabilizers and one or more buffering agents to deoxygenated water for injection and mixing until complete dissolution;
b) adding a chelating agent linked to somatostatin receptor binding organic moiety, mixing and adding sufficient amount of deoxygenated water for injection to obtain a bulk solution;
c) dispensing suitable volumes of the bulk solution into sterilized and depyrogenated vials;
d) lyophilizing; and
e) reconstituting with a solution of a radioisotope selected from copper-64, gallium-68, gallium-67, gallium-66, lutetium-177, yttrium-86, yttrium-90, technetium-99, indium-114, indium-111, scandium-47, scandium-44, scandium-43, zirconium-89, bismuth-213, bismuth-212, actinium-225, lead-212, rhenium-188, rhenium-186, and rubidium-82.

### Claim 8 (depends on 7)

The process of claim 7, wherein the lyophilization process comprises primary drying at a temperature of −32° C. and secondary drying at a temperature between 20° C. and 40° C.

### Claim 9 (depends on 7)

The process of claim 7, wherein the steps a), b) and c) are carried out under nitrogen environment.

### Claim 10

A reconstituted radiopharmaceutical composition in a single vial, comprising:
(a) from 0.045 mg/vial to 0.055 mg/vial of edotreotide (DOTATOC) or its pharmaceutically acceptable salt thereof, further radiolabeled with a radioisotope selected from gallium-68, lutetium-177 and actinium-225;
(b) from 2 mg/vial to 5 mg/vial of at least one stabilizer selected from the group consisting of ascorbic acid, sodium bisulfite, gentisic acid, glutamate, metabisulfite, monothioglycerol, propyl gallate, sulfite sodium, tocopherol alpha, thioglycolate, formaldehyde sulfoxylate sodium, histidine, melatonin and combinations thereof;
(c) from 45 mg/vial to 90 mg/vial of a buffer selected from the group consisting of sodium acetate, sodium succinate, tartrate, citrate, formate, HEPES buffer, lactate, TRIS, phosphate, borate, bicarbonate, carbonate, morpholine propanesulphonic acid and arginine and combinations thereof; and
(d) from 5 mg/vial to 15 mg/vial of a bulking agent selected from the group consisting of sodium chloride, gelatin, mannitol, inositol, sorbitol, polyethylene glycol, and polyvinyl pyrrolidone (PVP) and combinations thereof;
wherein the composition is free of sequestering agent and the radiochemical purity of radiolabeled composition is at least 95 percent immediately after reconstitution.

### Claim 11 (depends on 10)

The reconstituted radiopharmaceutical composition of claim 10, wherein the radioisotope is gallium-68.

### Claim 12 (depends on 10)

The reconstituted radiopharmaceutical composition of claim 10, wherein the edotreotide is present in the solution at a concentration of about 3 μg/mL-4 mg/mL.

### Claim 13 (depends on 10)

A method of diagnosis or treatment of neuroendocrine tumor in a subject comprising administration of the reconstituted radiopharmaceutical composition of claim 10.

### Claim 14 (depends on 11)

The reconstituted radiopharmaceutical composition of claim 11, wherein the composition comprises less than 3 percent of gallium-68 in colloidal form.

### Claim 15 (depends on 11)

The reconstituted radiopharmaceutical composition of claim 11, wherein the composition comprises less than 2 percent of gallium-68 (III) ion.

### Claim 16 (depends on 11)

The reconstituted radiopharmaceutical composition of claim 11, wherein the pH of the composition ranges from 5 to 6.

### Claim 17 (depends on 11)

The reconstituted radiopharmaceutical composition of claim 11, wherein the pH of the composition is within 0.5 pH units of the initial pH level after storage at 25±2° C. and 60±5% relative humidity for 3 hours.

### Claim 18 (depends on 11)

A process for preparing the reconstituted radiopharmaceutical composition of claim 11, the method comprising:
i) adding 0.5 mL of water to a lyophilized pharmaceutical composition, wherein the lyophilized pharmaceutical composition comprises:
(a) from 0.045 mg/vial to 0.055 mg/vial of edotreotide (DOTATOC) or its pharmaceutically acceptable salt thereof;
(b) from 2 mg/vial to 5 mg/vial of a stabilizer selected from the group consisting of ascorbic acid, sodium bisulfite, gentisic acid, glutamate, metabisulfite, monothioglycerol, propyl gallate, sulfite sodium, tocopherol alpha, thioglycolate, formaldehyde sulfoxylate sodium, histidine, and melatonin;
(c) from 45 mg/vial to 90 mg/vial of a buffer selected from the group consisting of sodium acetate, sodium succinate, tartrate, citrate, formate, HEPES buffer, lactate, TRIS, phosphate, borate, bicarbonate, carbonate, morpholine propanesulphonic acid and arginine and combinations thereof; and
(d) from 5 mg/vial to 15 mg/vial of a bulking agent selected from the group consisting of sodium chloride, gelatin, mannitol, inositol, sorbitol, polyethylene glycol, and polyvinyl pyrrolidone (PVP) and combinations thereof;
ii) adding gallium-68 in hydrochloric acid solution to the solution of step (a) after 1-2 minutes;
iii) heating the vial for 5-30 minutes at a temperature ranging from 60-120° C. and cooling for 2-10 minutes; and
iv) diluting the solution with saline at a volume of 4-14 mL, wherein the saline is sodium chloride present at a concentration of about 7 mg/mL-11 mg/mL.

### Claim 19 (depends on 18)

The process of claim 18, wherein the lyophilized pharmaceutical composition is contained in a vial of size between 10 mL-30 mL.

### Claim 20 (depends on 11)

A method of diagnosis of neuroendocrine tumor in a subject comprising administration of the reconstituted radiopharmaceutical composition of claim 11.
